Ticagrelor monotherapy after short DAPT in ACS: Time to turn theory into practice

Mattia Galli; Sebastiano Sciarretta

doi:10.1016/j.medj.2024.08.006

Ticagrelor monotherapy after short DAPT in ACS: Time to turn theory into practice

Med. 2024 Dec 13;5(12):1443-1445. doi: 10.1016/j.medj.2024.08.006.

Authors

Mattia Galli¹, Sebastiano Sciarretta²

Affiliations

¹ Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. Electronic address: [email protected].
² Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; IRCCS NeuroMed, Pozzilli, Italy.

PMID: 39674166
DOI: 10.1016/j.medj.2024.08.006

Abstract

Guidelines still recommend 12-month DAPT after acute coronary syndrome (ACS). This is possibly due to the insufficient power of most trials to detect hard ischemic endpoints, particularly in the subgroup of high ischemic-risk patients, such as those with ST-elevation ACS. Individual patient data meta-analyses play an important role in overcoming these limitations.

MeSH terms

Acute Coronary Syndrome* / drug therapy
Dual Anti-Platelet Therapy / methods
Humans
Platelet Aggregation Inhibitors* / administration & dosage
Platelet Aggregation Inhibitors* / therapeutic use
Ticagrelor* / administration & dosage
Ticagrelor* / therapeutic use

Substances

Ticagrelor
Platelet Aggregation Inhibitors